These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37210228)

  • 21. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.
    Mitchell E; Albon D
    Pediatr Pulmonol; 2024 Jul; 59(7):2009-2011. PubMed ID: 38607232
    [No Abstract]   [Full Text] [Related]  

  • 22. Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis.
    Lee TWR; Duff AJA
    Am J Respir Crit Care Med; 2024 Feb; 209(3):239-241. PubMed ID: 38113403
    [No Abstract]   [Full Text] [Related]  

  • 23. Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.
    Bacon DR; Stapleton A; Goralski JL; Ebert CS; Thorp BD; Nouraie M; Shaffer AD; Senior BA; Lee SE; Zemke AC; Kimple AJ
    Int Forum Allergy Rhinol; 2022 Feb; 12(2):223-226. PubMed ID: 34709729
    [No Abstract]   [Full Text] [Related]  

  • 24. Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor.
    Mingora CM; Caverly LJ
    J Cyst Fibros; 2024 Jan; 23(1):3-4. PubMed ID: 38307802
    [No Abstract]   [Full Text] [Related]  

  • 25. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare
    Burgel PR; Sermet-Gaudelus I; Girodon E; Kanaan R; Le Bihan J; Remus N; Ravoninjatovo B; Grenet D; Porzio M; Houdouin V; Le Clainche-Viala L; Durieu I; Nove-Josserand R; Languepin J; Coltey B; Guillaumot A; Audousset C; Chiron R; Weiss L; Fajac I; Da Silva J; Martin C;
    Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 38242629
    [No Abstract]   [Full Text] [Related]  

  • 26. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Dooney M; Saba T
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423592
    [No Abstract]   [Full Text] [Related]  

  • 27. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Burgel PR
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591
    [No Abstract]   [Full Text] [Related]  

  • 29. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor.
    Terlizzi V; Timpano S; Salvi M; Tosco A; Castaldo A; Fevola C; Leonetti G; Vitullo P; Sepe A; Badolato R; Salvatore D
    J Cyst Fibros; 2023 Nov; 22(6):1130-1132. PubMed ID: 37400299
    [No Abstract]   [Full Text] [Related]  

  • 31. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
    Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
    Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.
    Miller MJ; Foroozan R
    Can J Ophthalmol; 2022 Feb; 57(1):e6-e10. PubMed ID: 34058144
    [No Abstract]   [Full Text] [Related]  

  • 33. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.
    Safirstein J; Grant JJ; Clausen E; Savant D; Dezube R; Hong G
    J Cyst Fibros; 2021 May; 20(3):506-510. PubMed ID: 32736949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
    Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
    Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease.
    Djavid AR; Thompson AE; Irace AL; Gusman E; Altman K; DiMango EA; Keating CL
    Ann Am Thorac Soc; 2021 Nov; 18(11):1924-1927. PubMed ID: 34000224
    [No Abstract]   [Full Text] [Related]  

  • 36. Neuropsychiatric symptoms with elexacaftor/tezacaftor/ivacaftor: What does this mean for children?
    Pham H; Vandeleur M; Ranganathan S
    Pediatr Pulmonol; 2024 Mar; 59(3):537-539. PubMed ID: 37991124
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.
    O'Shea KM; O'Carroll OM; Carroll C; Grogan B; Connolly A; O'Shaughnessy L; Nicholson TT; Gallagher CG; McKone EF
    Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33154033
    [No Abstract]   [Full Text] [Related]  

  • 38. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation.
    Manika K; Diamantea F; Tsakona A; Kakolyris A; Sopiadou A; Kotoulas SC; Sionidou M; Kirvasili SS; Hadji-Mitrova M; Papadaki E; Chrysochoou EA; Hatziagorou E
    J Cyst Fibros; 2024 Jan; 23(1):29-31. PubMed ID: 37169616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. At-home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash.
    Muirhead C; Verzasconi D; Joshi S
    Pediatr Pulmonol; 2022 Jul; 57(7):1779-1781. PubMed ID: 35451238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.